Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance

Two phase 3 ATLAS trials demonstrated noninferiority of telavancin compared with vancomycin for complicated skin and skin structure infections. Data from these trials were retrospectively evaluated according to 2013 U.S. Food and Drug Administration (FDA) guidance on acute bacterial skin and skin st...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Pushkin, Richard, Barriere, Steven L., Wang, Whedy, Corey, G. Ralph, Stryjewski, Martin E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2015
Assuntos:
Clinical Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4576104/
https://ncbi.nlm.nih.gov/pubmed/26248356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00471-15
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados